Oct 28HHS draft policy lets licensed pharmacies compound six peptides, including BPC-157. What changed and what did not.
Skip to content
PeptideAgent

Compounding pharmacies in Alaska

By the PeptideAgent Editorial Team. Editorially reviewed, not clinically reviewed.  Last verified

The Alaska Board of Pharmacy regulates compounding pharmacies in Alaska. Compounded GLP-1 limited. How to check a pharmacy's license, plus listings with their verification status.

Alaska at a glance

Pharmacy regulator
Alaska Board of Pharmacy
503A framework
Follows the federal 503A framework
Telehealth prescribing
Regulatory: Telehealth allowed
Asynchronous prescribing
Regulatory: Async unclear
Compounded GLP-1 access
Regulatory: Compounded GLP-1 limited

Compounding pharmacies serving Alaska

No verified compounding pharmacies serving Alaska are listed yet. A provider appears here only after it passes the verification checklist, and those checks are still under way.

Looking for care now? Start with what the law allows where you live, then how a legitimate prescription works.

Run a pharmacy, clinic, or telehealth service? Apply for a listing.

Who regulates compounding pharmacies in Alaska

The Alaska Board of Pharmacy regulates pharmacy practice under AS 08.80 and 12 AAC 52; rule 12 AAC 52.440 requires a pharmacy or pharmacist that compounds to follow the Board's "Compounding Practices" guidelines pamphlet dated February 2008, which the rule incorporates by reference, and rule 12 AAC 52.430 requires a pharmacy that prepares or dispenses sterile pharmaceuticals (which includes injectable peptides) to adhere to the accepted standard of care. Alaska has no state bulks list, so peptide eligibility follows the federal 503A framework. Since November 27, 2023, the nonresident registration statute (AS 08.80.158) has been repealed and every pharmacy shipping prescription drugs into Alaska, wherever located, must hold an Alaska pharmacy license under AS 08.80.157 with a licensed pharmacist-in-charge. A telehealth prescription filled by an out-of-state pharmacy that has not obtained the Alaska license is being dispensed unlawfully. The Alaska Administrative Code text of 12 AAC 52.440 published by the Alaska Legislature, checked 2026-09-22, still incorporates the February 2008 pamphlet, so the rule has not been rewritten since the 2023 licensing changes. [1] [2] [3] [4] [5]

Compounded GLP-1 access in Alaska

Because Alaska now requires a full pharmacy license for any out-of-state pharmacy, Alaska patients using telehealth GLP-1 programs should confirm the dispensing pharmacy appears in the Division's professional license search as an Alaska-licensed pharmacy. [1] [2] [8]

Research use only sellers in Alaska

Any entity distributing prescription drugs into Alaska must be licensed by the Board of Pharmacy under AS 08.80.157, and peptides sold "for research use only" but marketed for human injection are unapproved new drugs under 21 U.S.C. 331 regardless of labeling. These products are not dispensed by a pharmacist, are not covered by Alaska's Telemedicine Business Registry protections, and carry no state consumer safeguards. [2] [9]

How to check a compounding pharmacy in Alaska

  1. Search the Alaska Board of Pharmacy license lookup for the pharmacy by name. A pharmacy based elsewhere needs whatever license or registration Alaska requires before it ships to you. [1] [2] [3] [4] [5]
  2. Ask whether it operates as a 503A pharmacy or a 503B outsourcing facility, and confirm a 503B claim against FDA's outsourcing facility information (see the verification checklist).
  3. Confirm the peptide can be lawfully compounded: check its status on the regulatory tracker or its peptide page before paying.
  4. Walk away from any seller that labels a peptide "research use only" or "not for human consumption". See the research use only section above for what that means in Alaska. [2] [9]

Common questions in Alaska

Can a mail-order pharmacy in another state ship compounded peptides to Alaska?

Only if it holds an Alaska pharmacy license. Since November 27, 2023, the nonresident registration under AS 08.80.158 no longer exists and all pharmacies serving Alaska patients are licensed under AS 08.80.157 with an Alaska-registered pharmacist-in-charge. Search the Division's professional license database before ordering. [1] [2]

Can an Alaska pharmacy compound BPC-157 or other unapproved peptides?

Only under a draft federal policy, and only within strict limits. On October 28, 2026 HHS released a draft enforcement discretion policy saying it will not take enforcement action against a state-licensed pharmacy that compounds BPC-157 as a single-ingredient product by an allowed route, on a patient-specific prescription, from an FDA-registered manufacturer's substance with a tested certificate of analysis, with serious adverse events reported to FDA. BPC-157 is still not FDA approved or on the 503A bulks list, the policy is not binding and HHS may revisit it, and blends such as Wolverine are not covered. FDA's drug center recommended against listing BPC-157; the advisory committee voted in favor (HHS policy, Appendix B). The draft covers only six single peptides (BPC-157, epitalon, KPV, MOTS-c, semax, TB-500); others, such as CJC-1295 and ipamorelin, are not covered. State law still applies: Alaska has no state bulks list, so peptide eligibility follows the federal 503A framework. [3] [6] [7] [10] [11]

All peptide legal questions for Alaska

Sources

  1. [1]Alaska Board of Pharmacy (Division of Corporations, Business and Professional Licensing)
  2. [2]Alaska Board of Pharmacy: statutes and regulations (AS 08.80 and 12 AAC 52, including the 2023 pharmacy licensing changes)
  3. [3]12 AAC 52.440, Guidelines relating to compounding practices
  4. [4]Alaska Legislature, Alaska Administrative Code: 12 AAC 52.430 (sterile pharmaceuticals) and 12 AAC 52.440 (compounding practices), accessed 2026-09-22
  5. [5]FDA: Section 503A of the Federal Food, Drug, and Cosmetic ActFDA
  6. [6]FDA: Certain bulk drug substances for use in compounding may present significant safety risks (503A and 503B category lists)FDA
  7. [7]FDA: Pharmacy Compounding Advisory CommitteeFDA
  8. [8]FDA: concerns with unapproved GLP-1 drugs used for weight loss, including shortage resolution and compounding grace periodsFDA
  9. [9]21 U.S.C. 331, Prohibited acts
  10. [10]Federal Register notice of availability: Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, FR Doc. 2026-22192 (Docket HHS-OASH-2026-0496)Federal Register, 2026
  11. [11]HHS: Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances (draft, with Appendix A and Appendix B)2026